Companies › Innovacell
1 active drug program in 1 registered trial: 1 Phase 3; Genitourinary; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| aSMDC Autologous skeletal muscle-derived cells for functional tissue repair | – | Phase 3 | Fecal Incontinence | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04976153 | aSMDC | Phase 3 | Fecal Incontinence | Genitourinary | Dec 2027 |
No annotated target.
–
Genexine Humacyte TolerogenixX Endo USA Inc., a Keenova Therapeutics Company Hansa Biopharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.